Cargando…

Treating pyruvate kinase deficiency with Mitapivat: a short communication

Detalles Bibliográficos
Autores principales:	Larik, Muhammad Omar, Shiraz, Moeez Ibrahim, Iftekhar, Muhammad Ashhal, Shiraz, Seemin Afshan, Shiraz, Maira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289629/ https://www.ncbi.nlm.nih.gov/pubmed/37363540 http://dx.doi.org/10.1097/MS9.0000000000000759

Ejemplares similares

Bombay Blood Group Phenotype Misdiagnosed As O Phenotype: A Case Report
por: Qadir, Hira, et al.
Publicado: (2023)

P1546: ACTIVATE-KIDST: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: Grace, R. F., et al.
Publicado: (2022)

P1547: ACTIVATE-KIDS: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
por: Grace, R. F., et al.
Publicado: (2022)

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: van Beers, E. J., et al.
Publicado: (2022)

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: van Beers, Eduard, et al.
Publicado: (2023)

Nasal spray (Zavegepant) for migraines: a mini-review
por: Larik, Muhammad Omar, et al.
Publicado: (2023)

Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
por: Al-Samkari, Hanny, et al.
Publicado: (2021)

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
por: Grace, Rachael F., et al.
Publicado: (2023)

P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: Barcellini, W., et al.
Publicado: (2022)

P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT
por: Al-Samkari, H., et al.
Publicado: (2022)

Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice
por: Mattè, Alessandro, et al.
Publicado: (2023)

P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
por: Kuo, K. H., et al.
Publicado: (2022)

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY
por: Grace, R. F., et al.
Publicado: (2022)

Fetuin-A levels in association with calcific aortic valve disease: A meta-analysis()
por: Larik, Muhammad Omar
Publicado: (2023)

Clinical Characteristics and Outcomes of Patients With Diabetes Admitted for COVID-19 Treatment in Dubai: Single-Centre Cross-Sectional Study
por: Bhatti, Rahila, et al.
Publicado: (2020)

P1543: MITAPIVAT DECREASES THE NEED FOR TRANSFUSIONS SECONDARY TO POORLY TOLERATED ANEMIA AND ACUTE EVENTS COMPARED TO PLACEBO IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
por: Al-Samkari, H., et al.
Publicado: (2022)

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K. H. M., et al.
Publicado: (2022)

Breaking Bad News: A contextual model for Pakistan
por: Baig, Lubna, et al.
Publicado: (2018)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023)

The silhouette technique: improving post-operative radiographs for planning of correction with a hexapod external fixator
por: Wright, Jonathan, et al.
Publicado: (2017)

Coronavirus disease (COVID-19) detection using X-ray images and enhanced DenseNet
por: Albahli, Saleh, et al.
Publicado: (2021)

Critical Product Features' Identification Using an Opinion Analyzer
por: Shamim, Azra, et al.
Publicado: (2014)

The Glenn procedure: Clinical outcomes in patients with congenital heart disease in pakistan
por: Tariq, Muhammad, et al.
Publicado: (2021)

Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease‐specific assessments
por: Salek, Sam, et al.
Publicado: (2020)

Molecular heterogeneity of pyruvate kinase deficiency
por: Bianchi, Paola, et al.
Publicado: (2020)

Pyruvate Kinase Deficiency Causing Priapism
por: Shankar, Vinay Hanyalu, et al.
Publicado: (2023)

Progressive librarianship: perspectives from Kenya and Britain, 1979-2010
por: Durrani, Shiraz
Publicado: (2014)

Black hole dynamics in a large number of dimensions
por: minwalla, shiraz
Publicado: (2017)

Black hole dynamics at large D
por: Minwalla, Shiraz
Publicado: (2016)

Nonlinear fluid dynamics from gravity
por: Shiraz Minwalla
Publicado: (2008)

Maturation and Patency Rates in Basilic Transposition Arteriovenous Fistula Under Regional Versus General Anesthesia: A Single-Center, Retrospective, Observational Study
por: Muhammad Saleh, Waryam, et al.
Publicado: (2021)

Characteristics, reasons and patterns of Road Traffic Injuries presenting in emergency department of a tertiary care public hospital in Karachi
por: Muhammad, Khaista, et al.
Publicado: (2022)

Microservice Application Scheduling in Multi-Tiered Fog-Computing-Enabled IoT
por: Ashraf, Maria, et al.
Publicado: (2023)

AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
por: Rab, Minke A.E., et al.
Publicado: (2020)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M.J., et al.
Publicado: (2023)

Commentary: Visual field testing: A distressing or an unpleasant experience!
por: Ali, M Shiraz
Publicado: (2022)

Comorbidities and complications in adults with pyruvate kinase deficiency
por: Boscoe, Audra N., et al.
Publicado: (2021)

Pyruvate kinase activator: A major breakthrough in the world of Hematology
por: Iqbal, Amna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ceenppj5dmu4u3v7e65g6i7jmb